Bavarian eases up on categorical statements on Covid-19 vaccine financing

Up until now, Bavarian Nordic's management has been adamant that it would only take the clinical development of the company's Covid-19 vaccine further if money came in from outside, but CEO Paul Chaplin might be starting to change his tune.

Bavarian Nordic President & CEO Paul Chaplin | Photo: Bavarian Nordic / PR

The Covid-19 situation has changed significantly since Bavarian Nordic made a deal with Adaptvac for the latter's coronavirus vaccine just under a year ago.

This may have played a part in changing Bavarian Nordic's rock-solid attitude on only taking the vaccine further than phase I of clinical development if the company was able to procure external financing.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs